Aggregation of a multidomain protein: A coagulation mechanism governs aggregation of a model IgG1 antibody under weak thermal stress

Protein Science

Volumn 19, Issue 2, 2010, Pages 279-290

  Andersen, Christian Beyschau ^a,b   Manno, Mauro ^a   Rischel, Christian ^b   Thórólfsson, Matthías ^b   Martorana, Vincenzo ^a  

^a CNR   (Italy)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Coagulation; Dynamic light scattering; Monoclonal IgG1 antibody; Multidomain; Protein aggregation; Rituximab; Tween 80

Indexed keywords

IMMUNOGLOBULIN G1;

ARTICLE; GEL PERMEATION CHROMATOGRAPHY; HYDRODYNAMICS; LIGHT SCATTERING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN DOMAIN; TEMPERATURE STRESS;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN G; MICE; MICROSCOPY, ATOMIC FORCE; MODELS, BIOLOGICAL; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; TEMPERATURE;

EID: 76749130326     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.309     Document Type: Article

References (57)

1. Chi EY, Krishnan S, Randolph TW, Carpenter JF (2003) Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 20:1325-1336.
2. Dobson CM (2003) Protein folding and misfolding. Nature 426:884-890.
3. Carrotta R, Manno M, Giordano FM, Longo A, Portale G, Martorana V, Biagio PLS (2009) Protein stability modulated by a conformational effector: effects of tri-fluoroethanol on bovine serum albumin. Phys Chem Chem Phys 11:4007-4018.
4. Frokjaer S, Otzen DE (2005) Protein drug stability: a formulation challenge. Nat Rev Drug Discov 4:298-306.
5. Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J (2008) Heterogeneity of monoclonal antibodies. J Pharm Sci 97:2426-2447.
6. Ban T, Morigaki K, Yagi H, Kawasaki T, Kobayashi A, Yuba S, Naiki H, Goto Y (2006) Real-time and single fibril observation of the formation of amyloid β spherulitic structures. J Biol Chem 281:33677-33683.
7. Grudzielanek S, Smirnovas V, Winter R (2006) Solvation-assisted pressure tuning of insulin fibrillation: from novel aggregation pathways to biotechnological applications. J Mol Biol 356:497-509.
8. Krebs MR, Devlin GL, Donald A (2005) Protein particulates: another generic form of protein aggregation? Biophys J 92:1336-1342.
9. Lomakin A, Chung DS, Benedek GB, Kirschner DA, Teplow DB (1996) On the nucleation and growth of amyloid β-protein fibrils: detection of nuclei and quantitation of rate constants. Proc Natl Acad Sci USA 93: 1125-1129.
10. De Young LR, Fink AL, Dill KA (1993) Aggregation of globular proteins. Acc Chem Res 26:614-620.
11. Roberts CJ (2007) Non-native protein aggregation kinetics. Biotechnol Bioeng 98:927-938.
12. Kendrick BS, Carpenter JF, Cleland JL, Randolph TW (1998) A transient expansion of the native state precedes aggregation of recombinant human interferon-γ. Proc Natl Acad Sci USA 95:14142-14146.
13. Wang W, Singh S, Zeng DL, King K, Nema S (2007) Antibody structure, instability, and formulation. J Pharm Sci 96:1-26.
14. Hermeling S, Aranha L, Damen JMA, Slijper M, Schellekens H, Crommelin DJA, Jiskoot W (2005) Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm Res 22:1997-2006.
15. De Groot AS, Scott DW (2007) Immunogenicity of protein therapeutics. Trends Immunol 28:482-490.
16. Rosenberg AS (2006) Effects of protein aggregates: an immunologic perspective. AAPS J 8:E501-E507.
17. Cartron G, Watier H, Golay J, Solal-Celigny P (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood 104:2635-2642.
18. Feder J, Jøssang T, Rosenqvist E (1984) Scaling behavior and cluster fractal dimension determined by light scattering from aggregating proteins. Phys Rev Lett 53:1403-1406.
19. Jøssang T, Feder J, Rosenqvist E (1985) Heat aggregation kinetics of human IgG. J Chem Phys 82:574-589.
20. Kiese S, Papppenberger A, Friess W, Mahler H-C (2008) Shaken, not stirred: mechanical stress testing of an IgG1 antibody. J Pharm Sci 97:4347-4366.
21. Mahler H-C, Müller R, Frieß W, Delille A, Matheus S (2005) Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur J Pharm Biopharm 59: 407-417.
22. Remmele RL, Jr, Callahan WJ, Krishnan S, Zhou L, Bondarenko PV, Nichols AC, Kleemann GR, Pipes GD, Park S, Fodor S, Kras E, Brems DN (2006) Active dimer of Epratuzumab provides insight into the complex nature of an antibody aggregate. J Pharm Sci 95: 126-145.
23. Rosenqvist E, Jøssang T, Feder J, Harbitz O (1986) Characterization of a heat-stable fraction of human IgG. J Prot Chem 5:323-333.
24. Van Buren N, Rehder D, Gadgil H, Matsumura M, Jacob J (2009) Elucidation of two major aggregation pathways in an IgG2 antibody. J Pharm Sci 98:3013-3030.
25. Li Y, Weiss WF, IV, Roberts CJ (2009) Characterization of high-molecular-weight nonnative aggregates and aggregation kinetics by size exclusion chromatography with inline multi-angle laser light scattering. J Pharm Sci 98:3997-4017.
26. Bauer R, Carrotta R, Rischel C, Øgendahl L (2000) Characterization and isolation of intermediates in β-lactoglobulin heat aggregation at high pH. Biophys J 79:1030-1038.
27. Ferrone F (1999) Analysis of protein aggregation kinetics. Methods Enzymol 309:256-274.
28. Pedersen JS, Otzen DE (2008) Amyloid - a state in many guises: survival of the fittest fibril fold. Protein Sci 17:2-10.
29. Garber E, Demarest SJ (2007) A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem Biophys Res Commun 355:751-757.
30. Ionescu RM, Vlasak J, Price C, Kirchmeier M (2008) Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci 97:1414-1426.
31. Demarest S, Glaser S (2008) Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Dev 11:675-687.
32. Sánchez-Ruiz JM (1992) Thereotical analysis of Lumry-Eyring models in differential scanning calorimetry. Biophys J 61:921-935.
33. Vermeer AWP, Norde W (2000) The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein. Biophys J 78:394-404.
34. Sánchez-Ruiz JM (1995) Differential scanning calorimetry of proteins. Subcell Biochem 24:133-176.
35. Sánchez-Ruiz JM, López-Lacomba JL, Cortijo M, Mateo PL (1988) Differential scanning calorimetry of the irreversible thermal denaturation of thermolysin. Biochemistry 27:1648-1652.
36. Harn N, Allan C, Oliver C, Middaugh CR (2007) Highly concentrated monoclonal antibody solutions: direct analysis of physical structure and thermal stability. J Pharm Sci 96:532-546.
37. Fisher ME, Burford RJ (1967) Theory of critical-point scattering and correlations. I. The Ising model. Phys Rev 156:583-622.
38. Gimel JC, Durand D, Nicolai T (1994) Structure and distribution of aggregates formed after heat-induced denaturation of globular proteins. Macromolecules 27:583-589.
39. Hagiwara T, Kumagai H, Matsunaga T, Nakamura K (1998) Analysis of aggregate structure in food protein gels with the concept of fractal. Biosci Biotechnol Biochem 61:1663-1667.
40. Carrotta R, Manno M, Bulone D, Martorana V, San Biagio PL (2005) Protofibril formation of amyloid β-protein at low pH via a non-cooperative elongation mechanism. J Biol Chem 280:30001-30008.
41. Le Bon C, Nicolai T, Durand D (1999) Kinetics of aggregation and gelation of globular proteins after heat-induced denaturation. Macromolecules 32:6120-6127.
42. Ball RC, Weitz DA, Witten TA, Leyvraz F (1987) Universal kinetics in reaction-limited aggregation. Phys Rev Lett 58:274-277.
43. Olivier BJ, Sorensen CM (1990) Variable aggregation rates in colloidal gold: kernel homogeneity dependence on aggregant concentration. Phys Rev A 41:2093-2100.
44. Andersen CB, Hisashi Y, Manno M, Martorana V, Ban T, Christiansen G, Otzen DE, Goto Y, Rischel C (2009) Branching in amyloid fibril growth. Biophys J 96: 1529-1536.
45. Manno M, Craparo EF, Podestà A, Bulone D, Carrotta R, Martorana V, Tiana G, San Biagio PL (2007) Kinetics of different processes in human insulin amyloid formation. J Mol Biol 366:258-274.
46. Vanni M (2000) Approximate population balance equations for aggregation-breakage processes. J Colloid Interface Sci 221:143-160.
47. Nohara D, Mizutani A, Sakai T (1999) Kinetic study on thermal denaturation of hen egg-white lysozyme involving precipitation. J Biosci Bioeng 87:199-205.
48. Librizzi F, Rischel C (2005) The kinetic behavior of insulin fibrillation is determined by heterogeneous nucleation pathways. Protein Sci 14:3129-3134.
49. McCarthy D, Goddard DH, Pell BK, Holborow EJ (1981) Intrinsically stable IgG aggregates. J Immunol Methods 41:63-74.
50. Bajaj H, Sharma VK, Badkar A, Zeng D, Nema S, Kalonia DS (2006) Protein structural conformation and not second virial coefficient relates to long-term irreversible aggregation of a monoclonal antibody and oval-bumin in solution. Pharm Res 23:1382-1394.
51. Plaza del Pino IM, Ibarra-Molero B, Sánchez-Ruiz JM (2000) Lower kinetic limit to protein thermal stability: a proposal regarding protein stability in vivo and its relation with misfolding diseases. Proteins 40:58-70.
52. Frisken BJ (2001) Revisiting the method of cumulants for the analysis of dynamic light-scattering data. Appl Opt 40:4087-4091.
53. García de la Torre J, Huertas ML, Carrasco B (2000) Calculation of hydrodynamic properties of globular proteins from their atomic-level structure. Biophys J 78: 719-730.
54. Saphire EO, Parren PWHI, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA (2001) Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design. Science 293:1155-1159.
55. Nečas D, Klapetek P (2008) Gwyddion 2.10 SPM data analysis program. Available at: http://gwyddion.net. Accessed October 2009.
56. Hawe A, Sutter M, Jiskoot W (2008) Extrinsic fluorescent dyes as tools for protein characterization. Pharm Res 25:1487-1499.
57. Pantoliano MW, Petrella EC, Kwasnoski JD, Lobanov VS, Myslik J, Graf E, Carver T, Asel E, Springer BA, Lane P, Salemme FR (2001) High-density miniaturized thermal shift assays as a general strategy for drug discovery. J Biomol Screen 6:429-440.